GlassScriptPhysician profile
Alberto Parra
NPI 1376836718
$29,510.67
in general payments reported to CMS, 2019-2025
69 companies · $3,043 in 2025
The $3,043 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,486 · 2020: $792 · 2021: $383 · 2022: $966 · 2023: $3,240 · 2024: $19K · 2025: $3,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $8,723 · Travel and Lodging: $634 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,510.00 |
| Food and Beverage | $8,722.69 |
| Travel and Lodging | $634.12 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $16,559.42 | 2023-2024 | Bavencio |
| Janssen Biotech, INC. | $2,583.37 | 2019-2025 | Erleada, Akeega, Carvykti |
| Daiichi Sankyo INC. | $995.76 | 2019-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $830.02 | 2019-2025 | Padcev, Xtandi |
| Pfizer INC. | $762.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $750.31 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $530.27 | 2019-2025 | |
| Puma Biotechnology, INC. | $398.11 | 2019-2021 | |
| Gilead Sciences, INC. | $373.14 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $362.28 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $350.77 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Abbvie INC. | $336.02 | 2019-2025 | |
| Celgene Corporation | $331.44 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Johnson & Johnson Health Care Systems INC. | $272.51 | 2024-2025 | Stelara, Darzalex |
| Exelixis INC. | $272.28 | 2019-2025 | Cabometyx |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $258.30 | 2019-2023 | Sir-Spheres Microspheres |
| Incyte Corporation | $254.90 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $215.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $184.85 | 2019-2025 | Jemperli, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $182.86 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $169.98 | 2019-2025 | |
| Amgen INC. | $162.74 | 2019-2023 | Lumakras |
| Verastem, INC. | $157.89 | 2019-2020 | |
| Blueprint Medicines Corporation | $139.76 | 2024 | Ayvakit |
| Seagen INC. | $127.44 | 2019-2023 | Padcev, Tukysa |
| Intuitive Surgical, INC. | $125.00 | 2023 | |
| Dendreon Pharmaceuticals LLC | $124.80 | 2020-2025 | Provenge |
| Sun Pharmaceutical Industries INC. | $101.33 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $95.23 | 2019-2025 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $90.68 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $82.39 | 2019-2025 | Fruzaqla |
| Teva Pharmaceuticals USA, INC. | $79.31 | 2019 | |
| Genzyme Corporation | $79.28 | 2023-2025 | |
| Tersera Therapeutics LLC | $72.87 | 2025 | Zoladex, Quzyttir |
| Caris Mpi, INC. | $69.78 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $54.57 | 2019-2022 | |
| Genentech USA, INC. | $53.14 | 2019-2020 | |
| Foundation Medicine, INC. | $52.85 | 2023 | |
| Genmab U.S., INC. | $51.18 | 2024 | Tivdak |
| Tg Therapeutics, INC. | $49.99 | 2021 | |
| Aveo Pharmaceuticals, INC. | $48.37 | 2024-2025 | |
| Kite Pharma, INC. | $43.25 | 2024-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.93 | 2024-2025 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $42.46 | 2020 | |
| Novocure INC. | $40.90 | 2020-2022 | |
| Fennec Pharmaceuticals, INC. | $38.03 | 2025 | Fyarro |
| Immunocore Limited | $37.53 | 2024-2025 | Kimmtrak |
| Acrotech Biopharma INC. | $36.70 | 2022-2023 | Beleodaq |
| Tesaro, INC. | $33.60 | 2019 | |
| Springworks Therapeutics, INC. | $30.97 | 2025 | Gomekli, Ogsiveo |
| Beigene USA, INC. | $26.49 | 2020 | |
| Servier Pharmaceuticals LLC | $24.90 | 2024 | |
| Tempus Ai, INC | $24.25 | 2024 | |
| Coherus Oncology, INC. | $23.33 | 2020 | |
| Spectrum Pharmaceuticals INC. | $22.58 | 2025 | Rolvedon |
| Tolmar, INC. | $22.30 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $22.30 | 2025 | Rubraca |
| Heron Therapeutics, INC. | $21.34 | 2019 | |
| Tactile Systems Technology INC | $20.41 | 2023 | Flexitouch Plus, Entre Plus |
| Stemline Therapeutics INC. | $19.62 | 2024 | Orserdu |
| Karyopharm Therapeutics INC. | $19.20 | 2023 | Xpovio |
| Taiho Oncology, INC. | $19.07 | 2019 | |
| Clovis Oncology, INC. | $18.57 | 2019 | |
| Sobi, INC | $18.37 | 2024 | |
| Menarini Silicon Biosystems, INC. | $14.84 | 2023 | Cellsearch |
| Mylan Institutional INC. | $14.49 | 2019 | |
| Epizyme, INC. | $14.34 | 2021 | |
| Dova Pharmaceuticals | $14.29 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Parra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.